Drug delivery to central nervous system (CNS) diseases is very challenging since the
presence of the innate blood–brain barrier (BBB) and the blood-cerebrospinal fluid barrier …

Thrombotic occlusions of blood vessels are responsible for life-threatening cardiovascular
disorders such as myocardial infarction, ischemic stroke, and venous thromboembolism …

Conventional thrombolytic drugs for vascular blockage such as tissue plasminogen activator
(tPA) are challenged by the low bioavailability, off-target side effects and limited penetration …

During the past two decades, the clinical use of biopharmaceutical products has markedly
increased because of their obvious advantages over conventional small-molecule drug …

Nanobubbles (NBs) have recently garnered widespread attention for their potential use as
dual diagnostic and therapeutic agents. Similar to their micron-sized relatives …

Encapsulated microbubbles have been developed over the past two decades to provide
improvements both in imaging as well as new therapeutic applications. Microbubble contrast …

Introduction: Thrombolysis with intravenous tissue plasminogen activator (tPA) is the only
FDA approved treatment for patients with acute ischemic stroke, but its use is limited by …

Microbubbles (MBs) were observed for the first time in vivo as a curious consequence of
quick saline injection during ultrasound (US) imaging of the aortic root, more than 50 years …

Stroke is a major cause of disability worldwide, and is the second leading cause of death
after ischemic heart disease. Until recently, tissue‐type plasminogen activator (t‐PA) was the …

Cardiovascular diseases (CVDs) are the world's leading cause of mortality and represent a
large contributor to the costs of medical care. Although tremendous progress has been …